CCRN Sale to Knox Lane at $13.25 Sparks Law Firm Investigation

What happened

On May 13, 2026, law firm Wohl & Fruchter announced an investigation into the fairness of the $13.25 per share cash sale of Cross Country Healthcare to private equity firm Knox Lane. This price represents a roughly 46% premium to CCRN's recent trading around $9.06 but sits below the $15 bull case value in our analysis and the company's book value per share of about $12.55. The investigation underscores concerns that the board may have accepted a lowball offer amidst a downcycle, potentially failing to maximize shareholder value. The deal comes after the failed Aya Healthcare merger and a period of significant revenue decline, but the company holds a net cash position and has been executing buybacks. Investors should monitor for potential competing bids, a higher offer from Knox Lane, or legal challenges that could pressure the board to seek a better price.

Implication

For investors, the $13.25 bid signals a near-term price floor but likely undervalues the company's net cash and long-term stabilization prospects. The law firm investigation could lead to a higher bid if other buyers emerge or if the board is forced to run a fair process. However, the risk of the deal closing at $13.25 is real given the company's recent struggles. Our base case valuation of $12 is below the offer, so the bid is not a clear win. We recommend holding shares and awaiting developments, as the investigation may prompt a higher offer or the deal may fall through, leaving the stock to trade back to $9-12.

Thesis delta

The news of the sale and investigation shifts the thesis from a cyclical recovery play to a pending sale arbitrage. The low acquisition price relative to book value and bull case suggests the board may have accepted a suboptimal offer, potentially depriving shareholders of upside if the company stabilizes. The investigation increases the probability of a higher bid or a no-go scenario, making the stock a high-risk hold rather than a buy for recovery.